Details
Stereochemistry | RACEMIC |
Molecular Formula | C18H14F4N2O4S |
Molecular Weight | 430.3751 |
Optical Activity | ( + / - ) |
Defined Stereocenters | 0 / 1 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CC(CS(=O)(=O)c1ccc(cc1)F)(C(=Nc2ccc(C#N)c(c2)C(F)(F)F)O)O
InChI
InChIKey=LKJPYSCBVHEWIU-UHFFFAOYSA-N
InChI=1S/C18H14F4N2O4S/c1-17(26,10-29(27,28)14-6-3-12(19)4-7-14)16(25)24-13-5-2-11(9-23)15(8-13)18(20,21)22/h2-8,26H,10H2,1H3,(H,24,25)
Bicalutamide (brand name Casodex) is an oral non-steroidal anti-androgen for prostate cancer. It is indicated for use in combination therapy with a luteinizing hormone-releasing hormone (LHRH) analog for the treatment of Stage D2 metastatic carcinoma of the prostate. Bicalutamide competitively inhibits the action of androgens by binding to cytosol androgen receptors in the target tissue. Prostatic carcinoma is known to be androgen sensitive and responds to treatment that counteracts the effect of androgen and/or removes the source of androgen. When CASODEX is combined with luteinizing hormone releasing hormone (LHRH) analog therapy, the suppression of serum testosterone induced by the LHRH analog is not affected. Bicalutamide is well-absorbed following oral administration, although the absolute bioavailability is unknown. Bicalutamide undergoes stereospecific metabolism. The S (inactive) isomer is metabolized primarily by glucuronidation. The R (active) isomer also undergoes glucuronidation but is predominantly oxidized to an inactive metabolite followed by glucuronidation. Both the parent and metabolite glucuronides are eliminated in the urine and feces. The S-enantiomer is rapidly cleared relative to the R-enantiomer, with the R-enantiomer accounting for about 99% of total steady-state plasma levels.
CNS Activity
Sources: https://www.ncbi.nlm.nih.gov/pubmed/8560673
Curator's Comment:: The peripheral selectivity of bicalutamide has been shown to be due to poor penetration across the blood-brain barrier: tissue distribution studies with [3H]bicalutamide show that although it is concentrated in the organs of metabolism and secretion as well as in the prostate, the pituitary glands, and the seminal vesicles, levels in the hypothalamus and the central nervous system (CNS) are much lower than in blood.
Originator
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL1871 Sources: https://www.ncbi.nlm.nih.gov/pubmed/11931851 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | CASODEX Approved UseBicalutamide 50 mg daily is indicated for use in combination therapy with a luteinizing hormone-releasing hormone (LHRH) analog for the treatment of Stage D2 metastatic carcinoma of the prostate. Bicalutamide 150 mg daily is not approved for use alone or with other treatments [see Clinical Studies (14.2) Launch Date8.1276482E11 |
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
810.7 μg/L EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/22331758 |
50 mg single, oral dose: 50 mg route of administration: Oral experiment type: SINGLE co-administered: |
BICALUTAMIDE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
AUC
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
202.5 μg × h/mL EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/22331758 |
50 mg single, oral dose: 50 mg route of administration: Oral experiment type: SINGLE co-administered: |
BICALUTAMIDE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
T1/2
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
5.8 day |
50 mg single, oral dose: 50 mg route of administration: Oral experiment type: SINGLE co-administered: GONADORELIN |
BICALUTAMIDE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
|
146.4 h EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/22331758 |
50 mg single, oral dose: 50 mg route of administration: Oral experiment type: SINGLE co-administered: |
BICALUTAMIDE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
Funbound
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
4% |
50 mg single, oral dose: 50 mg route of administration: Oral experiment type: SINGLE co-administered: GONADORELIN |
BICALUTAMIDE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
Doses
Dose | Population | Adverse events |
---|---|---|
600 mg 1 times / day multiple, oral Highest studied dose Dose: 600 mg, 1 times / day Route: oral Route: multiple Dose: 600 mg, 1 times / day Sources: |
unhealthy, 72.1 years (range: 56-84 years) n = 42 Health Status: unhealthy Condition: prostate cancer Age Group: 72.1 years (range: 56-84 years) Sex: M Population Size: 42 Sources: |
Other AEs: Gynaecomastia, Breast pain... Other AEs: Gynaecomastia (45.2%) Sources: Breast pain (57.1%) Hot flushes (16.7%) Constipation (31%) Dry skin (2.4%) Insomnia (9.5%) Rash (11.9%) Back pain (14.3%) Asthenia (19%) Diarrhoea (19%) Urinary tract infection (16.7%) Arthralgia (11.9%) Pharyngitis (14.3%) Pain (23.8%) |
200 mg 1 times / day multiple, oral Highest studied dose Dose: 200 mg, 1 times / day Route: oral Route: multiple Dose: 200 mg, 1 times / day Sources: |
unhealthy, adult n = 29 Health Status: unhealthy Condition: prostate cancer Age Group: adult Sex: M Population Size: 29 Sources: |
Other AEs: Back pain, Constipation... Other AEs: Back pain (6.9%) Sources: Constipation (10.3%) Libido decreased (50%) Impotence (57%) Dyspepsia (6.9%) Dysuria (6.9%) Haematuria (6.9%) Pain (17.2%) Pelvic pain (6.9%) Somnolence (6.9%) Urinary incontinence (6.9%) Urinary urgency (6.9%) Weight gain (10.3%) Gynaecomastia (79%) Breast tenderness (79%) Hot flushes (41%) |
50 mg 1 times / day multiple, oral Recommended Dose: 50 mg, 1 times / day Route: oral Route: multiple Dose: 50 mg, 1 times / day Co-administed with:: LHRH analog Sources: |
unhealthy, adult n = 401 Health Status: unhealthy Condition: prostate cancer Age Group: adult Sex: M Population Size: 401 Sources: |
Other AEs: General body pain, Back pain... Other AEs: General body pain (35%) Sources: Back pain (25%) Asthenia (22%) Pelvic pain (21%) Infection (18%) Abdominal pain (11%) Chest pain (8%) Headache (7%) Flu syndrome (7%) Hot flashes (53%) Hypertension (8%) Constipation (22%) Nausea (15%) Diarrhea (12%) Liver function test increased (7%) Dyspepsia (7%) Flatulence (6%) Anorexia (6%) Vomiting (6%) Anemia (11%) Peripheral edema (13%) Weight loss (7%) Hyperglycemia (6%) Alkaline phosphatase increased (5%) Weight gain (5%) Bone pain (9%) Myasthenia (7%) Arthritis (5%) Fracture pathological (4%) Dizziness (10%) Paresthesia (8%) Insomnia (7%) Anxiety (5%) Depression (4%) Dyspnea (13%) Cough increased (8%) Pharyngitis (8%) Bronchitis (6%) Pneumonia (4%) Rhinitis (4%) Rash (9%) Sweating (6%) Nocturia (12%) Hematuria (12%) Urinary tract infection (9%) Gynecomastia (9%) Impotence (7%) Breast pain (6%) Urinary frequency (6%) Urinary retention (5%) Urination impaired (5%) Urinary incontinence (4%) |
AEs
AE | Significance | Dose | Population |
---|---|---|---|
Arthralgia | 11.9% | 600 mg 1 times / day multiple, oral Highest studied dose Dose: 600 mg, 1 times / day Route: oral Route: multiple Dose: 600 mg, 1 times / day Sources: |
unhealthy, 72.1 years (range: 56-84 years) n = 42 Health Status: unhealthy Condition: prostate cancer Age Group: 72.1 years (range: 56-84 years) Sex: M Population Size: 42 Sources: |
Rash | 11.9% | 600 mg 1 times / day multiple, oral Highest studied dose Dose: 600 mg, 1 times / day Route: oral Route: multiple Dose: 600 mg, 1 times / day Sources: |
unhealthy, 72.1 years (range: 56-84 years) n = 42 Health Status: unhealthy Condition: prostate cancer Age Group: 72.1 years (range: 56-84 years) Sex: M Population Size: 42 Sources: |
Back pain | 14.3% | 600 mg 1 times / day multiple, oral Highest studied dose Dose: 600 mg, 1 times / day Route: oral Route: multiple Dose: 600 mg, 1 times / day Sources: |
unhealthy, 72.1 years (range: 56-84 years) n = 42 Health Status: unhealthy Condition: prostate cancer Age Group: 72.1 years (range: 56-84 years) Sex: M Population Size: 42 Sources: |
Pharyngitis | 14.3% | 600 mg 1 times / day multiple, oral Highest studied dose Dose: 600 mg, 1 times / day Route: oral Route: multiple Dose: 600 mg, 1 times / day Sources: |
unhealthy, 72.1 years (range: 56-84 years) n = 42 Health Status: unhealthy Condition: prostate cancer Age Group: 72.1 years (range: 56-84 years) Sex: M Population Size: 42 Sources: |
Hot flushes | 16.7% | 600 mg 1 times / day multiple, oral Highest studied dose Dose: 600 mg, 1 times / day Route: oral Route: multiple Dose: 600 mg, 1 times / day Sources: |
unhealthy, 72.1 years (range: 56-84 years) n = 42 Health Status: unhealthy Condition: prostate cancer Age Group: 72.1 years (range: 56-84 years) Sex: M Population Size: 42 Sources: |
Urinary tract infection | 16.7% | 600 mg 1 times / day multiple, oral Highest studied dose Dose: 600 mg, 1 times / day Route: oral Route: multiple Dose: 600 mg, 1 times / day Sources: |
unhealthy, 72.1 years (range: 56-84 years) n = 42 Health Status: unhealthy Condition: prostate cancer Age Group: 72.1 years (range: 56-84 years) Sex: M Population Size: 42 Sources: |
Asthenia | 19% | 600 mg 1 times / day multiple, oral Highest studied dose Dose: 600 mg, 1 times / day Route: oral Route: multiple Dose: 600 mg, 1 times / day Sources: |
unhealthy, 72.1 years (range: 56-84 years) n = 42 Health Status: unhealthy Condition: prostate cancer Age Group: 72.1 years (range: 56-84 years) Sex: M Population Size: 42 Sources: |
Diarrhoea | 19% | 600 mg 1 times / day multiple, oral Highest studied dose Dose: 600 mg, 1 times / day Route: oral Route: multiple Dose: 600 mg, 1 times / day Sources: |
unhealthy, 72.1 years (range: 56-84 years) n = 42 Health Status: unhealthy Condition: prostate cancer Age Group: 72.1 years (range: 56-84 years) Sex: M Population Size: 42 Sources: |
Dry skin | 2.4% | 600 mg 1 times / day multiple, oral Highest studied dose Dose: 600 mg, 1 times / day Route: oral Route: multiple Dose: 600 mg, 1 times / day Sources: |
unhealthy, 72.1 years (range: 56-84 years) n = 42 Health Status: unhealthy Condition: prostate cancer Age Group: 72.1 years (range: 56-84 years) Sex: M Population Size: 42 Sources: |
Pain | 23.8% | 600 mg 1 times / day multiple, oral Highest studied dose Dose: 600 mg, 1 times / day Route: oral Route: multiple Dose: 600 mg, 1 times / day Sources: |
unhealthy, 72.1 years (range: 56-84 years) n = 42 Health Status: unhealthy Condition: prostate cancer Age Group: 72.1 years (range: 56-84 years) Sex: M Population Size: 42 Sources: |
Constipation | 31% | 600 mg 1 times / day multiple, oral Highest studied dose Dose: 600 mg, 1 times / day Route: oral Route: multiple Dose: 600 mg, 1 times / day Sources: |
unhealthy, 72.1 years (range: 56-84 years) n = 42 Health Status: unhealthy Condition: prostate cancer Age Group: 72.1 years (range: 56-84 years) Sex: M Population Size: 42 Sources: |
Gynaecomastia | 45.2% | 600 mg 1 times / day multiple, oral Highest studied dose Dose: 600 mg, 1 times / day Route: oral Route: multiple Dose: 600 mg, 1 times / day Sources: |
unhealthy, 72.1 years (range: 56-84 years) n = 42 Health Status: unhealthy Condition: prostate cancer Age Group: 72.1 years (range: 56-84 years) Sex: M Population Size: 42 Sources: |
Breast pain | 57.1% | 600 mg 1 times / day multiple, oral Highest studied dose Dose: 600 mg, 1 times / day Route: oral Route: multiple Dose: 600 mg, 1 times / day Sources: |
unhealthy, 72.1 years (range: 56-84 years) n = 42 Health Status: unhealthy Condition: prostate cancer Age Group: 72.1 years (range: 56-84 years) Sex: M Population Size: 42 Sources: |
Insomnia | 9.5% | 600 mg 1 times / day multiple, oral Highest studied dose Dose: 600 mg, 1 times / day Route: oral Route: multiple Dose: 600 mg, 1 times / day Sources: |
unhealthy, 72.1 years (range: 56-84 years) n = 42 Health Status: unhealthy Condition: prostate cancer Age Group: 72.1 years (range: 56-84 years) Sex: M Population Size: 42 Sources: |
Constipation | 10.3% | 200 mg 1 times / day multiple, oral Highest studied dose Dose: 200 mg, 1 times / day Route: oral Route: multiple Dose: 200 mg, 1 times / day Sources: |
unhealthy, adult n = 29 Health Status: unhealthy Condition: prostate cancer Age Group: adult Sex: M Population Size: 29 Sources: |
Weight gain | 10.3% | 200 mg 1 times / day multiple, oral Highest studied dose Dose: 200 mg, 1 times / day Route: oral Route: multiple Dose: 200 mg, 1 times / day Sources: |
unhealthy, adult n = 29 Health Status: unhealthy Condition: prostate cancer Age Group: adult Sex: M Population Size: 29 Sources: |
Pain | 17.2% | 200 mg 1 times / day multiple, oral Highest studied dose Dose: 200 mg, 1 times / day Route: oral Route: multiple Dose: 200 mg, 1 times / day Sources: |
unhealthy, adult n = 29 Health Status: unhealthy Condition: prostate cancer Age Group: adult Sex: M Population Size: 29 Sources: |
Hot flushes | 41% | 200 mg 1 times / day multiple, oral Highest studied dose Dose: 200 mg, 1 times / day Route: oral Route: multiple Dose: 200 mg, 1 times / day Sources: |
unhealthy, adult n = 29 Health Status: unhealthy Condition: prostate cancer Age Group: adult Sex: M Population Size: 29 Sources: |
Libido decreased | 50% | 200 mg 1 times / day multiple, oral Highest studied dose Dose: 200 mg, 1 times / day Route: oral Route: multiple Dose: 200 mg, 1 times / day Sources: |
unhealthy, adult n = 29 Health Status: unhealthy Condition: prostate cancer Age Group: adult Sex: M Population Size: 29 Sources: |
Impotence | 57% | 200 mg 1 times / day multiple, oral Highest studied dose Dose: 200 mg, 1 times / day Route: oral Route: multiple Dose: 200 mg, 1 times / day Sources: |
unhealthy, adult n = 29 Health Status: unhealthy Condition: prostate cancer Age Group: adult Sex: M Population Size: 29 Sources: |
Back pain | 6.9% | 200 mg 1 times / day multiple, oral Highest studied dose Dose: 200 mg, 1 times / day Route: oral Route: multiple Dose: 200 mg, 1 times / day Sources: |
unhealthy, adult n = 29 Health Status: unhealthy Condition: prostate cancer Age Group: adult Sex: M Population Size: 29 Sources: |
Dyspepsia | 6.9% | 200 mg 1 times / day multiple, oral Highest studied dose Dose: 200 mg, 1 times / day Route: oral Route: multiple Dose: 200 mg, 1 times / day Sources: |
unhealthy, adult n = 29 Health Status: unhealthy Condition: prostate cancer Age Group: adult Sex: M Population Size: 29 Sources: |
Dysuria | 6.9% | 200 mg 1 times / day multiple, oral Highest studied dose Dose: 200 mg, 1 times / day Route: oral Route: multiple Dose: 200 mg, 1 times / day Sources: |
unhealthy, adult n = 29 Health Status: unhealthy Condition: prostate cancer Age Group: adult Sex: M Population Size: 29 Sources: |
Haematuria | 6.9% | 200 mg 1 times / day multiple, oral Highest studied dose Dose: 200 mg, 1 times / day Route: oral Route: multiple Dose: 200 mg, 1 times / day Sources: |
unhealthy, adult n = 29 Health Status: unhealthy Condition: prostate cancer Age Group: adult Sex: M Population Size: 29 Sources: |
Pelvic pain | 6.9% | 200 mg 1 times / day multiple, oral Highest studied dose Dose: 200 mg, 1 times / day Route: oral Route: multiple Dose: 200 mg, 1 times / day Sources: |
unhealthy, adult n = 29 Health Status: unhealthy Condition: prostate cancer Age Group: adult Sex: M Population Size: 29 Sources: |
Somnolence | 6.9% | 200 mg 1 times / day multiple, oral Highest studied dose Dose: 200 mg, 1 times / day Route: oral Route: multiple Dose: 200 mg, 1 times / day Sources: |
unhealthy, adult n = 29 Health Status: unhealthy Condition: prostate cancer Age Group: adult Sex: M Population Size: 29 Sources: |
Urinary incontinence | 6.9% | 200 mg 1 times / day multiple, oral Highest studied dose Dose: 200 mg, 1 times / day Route: oral Route: multiple Dose: 200 mg, 1 times / day Sources: |
unhealthy, adult n = 29 Health Status: unhealthy Condition: prostate cancer Age Group: adult Sex: M Population Size: 29 Sources: |
Urinary urgency | 6.9% | 200 mg 1 times / day multiple, oral Highest studied dose Dose: 200 mg, 1 times / day Route: oral Route: multiple Dose: 200 mg, 1 times / day Sources: |
unhealthy, adult n = 29 Health Status: unhealthy Condition: prostate cancer Age Group: adult Sex: M Population Size: 29 Sources: |
Breast tenderness | 79% | 200 mg 1 times / day multiple, oral Highest studied dose Dose: 200 mg, 1 times / day Route: oral Route: multiple Dose: 200 mg, 1 times / day Sources: |
unhealthy, adult n = 29 Health Status: unhealthy Condition: prostate cancer Age Group: adult Sex: M Population Size: 29 Sources: |
Gynaecomastia | 79% | 200 mg 1 times / day multiple, oral Highest studied dose Dose: 200 mg, 1 times / day Route: oral Route: multiple Dose: 200 mg, 1 times / day Sources: |
unhealthy, adult n = 29 Health Status: unhealthy Condition: prostate cancer Age Group: adult Sex: M Population Size: 29 Sources: |
Dizziness | 10% | 50 mg 1 times / day multiple, oral Recommended Dose: 50 mg, 1 times / day Route: oral Route: multiple Dose: 50 mg, 1 times / day Co-administed with:: LHRH analog Sources: |
unhealthy, adult n = 401 Health Status: unhealthy Condition: prostate cancer Age Group: adult Sex: M Population Size: 401 Sources: |
Abdominal pain | 11% | 50 mg 1 times / day multiple, oral Recommended Dose: 50 mg, 1 times / day Route: oral Route: multiple Dose: 50 mg, 1 times / day Co-administed with:: LHRH analog Sources: |
unhealthy, adult n = 401 Health Status: unhealthy Condition: prostate cancer Age Group: adult Sex: M Population Size: 401 Sources: |
Anemia | 11% | 50 mg 1 times / day multiple, oral Recommended Dose: 50 mg, 1 times / day Route: oral Route: multiple Dose: 50 mg, 1 times / day Co-administed with:: LHRH analog Sources: |
unhealthy, adult n = 401 Health Status: unhealthy Condition: prostate cancer Age Group: adult Sex: M Population Size: 401 Sources: |
Diarrhea | 12% | 50 mg 1 times / day multiple, oral Recommended Dose: 50 mg, 1 times / day Route: oral Route: multiple Dose: 50 mg, 1 times / day Co-administed with:: LHRH analog Sources: |
unhealthy, adult n = 401 Health Status: unhealthy Condition: prostate cancer Age Group: adult Sex: M Population Size: 401 Sources: |
Hematuria | 12% | 50 mg 1 times / day multiple, oral Recommended Dose: 50 mg, 1 times / day Route: oral Route: multiple Dose: 50 mg, 1 times / day Co-administed with:: LHRH analog Sources: |
unhealthy, adult n = 401 Health Status: unhealthy Condition: prostate cancer Age Group: adult Sex: M Population Size: 401 Sources: |
Nocturia | 12% | 50 mg 1 times / day multiple, oral Recommended Dose: 50 mg, 1 times / day Route: oral Route: multiple Dose: 50 mg, 1 times / day Co-administed with:: LHRH analog Sources: |
unhealthy, adult n = 401 Health Status: unhealthy Condition: prostate cancer Age Group: adult Sex: M Population Size: 401 Sources: |
Dyspnea | 13% | 50 mg 1 times / day multiple, oral Recommended Dose: 50 mg, 1 times / day Route: oral Route: multiple Dose: 50 mg, 1 times / day Co-administed with:: LHRH analog Sources: |
unhealthy, adult n = 401 Health Status: unhealthy Condition: prostate cancer Age Group: adult Sex: M Population Size: 401 Sources: |
Peripheral edema | 13% | 50 mg 1 times / day multiple, oral Recommended Dose: 50 mg, 1 times / day Route: oral Route: multiple Dose: 50 mg, 1 times / day Co-administed with:: LHRH analog Sources: |
unhealthy, adult n = 401 Health Status: unhealthy Condition: prostate cancer Age Group: adult Sex: M Population Size: 401 Sources: |
Nausea | 15% | 50 mg 1 times / day multiple, oral Recommended Dose: 50 mg, 1 times / day Route: oral Route: multiple Dose: 50 mg, 1 times / day Co-administed with:: LHRH analog Sources: |
unhealthy, adult n = 401 Health Status: unhealthy Condition: prostate cancer Age Group: adult Sex: M Population Size: 401 Sources: |
Infection | 18% | 50 mg 1 times / day multiple, oral Recommended Dose: 50 mg, 1 times / day Route: oral Route: multiple Dose: 50 mg, 1 times / day Co-administed with:: LHRH analog Sources: |
unhealthy, adult n = 401 Health Status: unhealthy Condition: prostate cancer Age Group: adult Sex: M Population Size: 401 Sources: |
Pelvic pain | 21% | 50 mg 1 times / day multiple, oral Recommended Dose: 50 mg, 1 times / day Route: oral Route: multiple Dose: 50 mg, 1 times / day Co-administed with:: LHRH analog Sources: |
unhealthy, adult n = 401 Health Status: unhealthy Condition: prostate cancer Age Group: adult Sex: M Population Size: 401 Sources: |
Asthenia | 22% | 50 mg 1 times / day multiple, oral Recommended Dose: 50 mg, 1 times / day Route: oral Route: multiple Dose: 50 mg, 1 times / day Co-administed with:: LHRH analog Sources: |
unhealthy, adult n = 401 Health Status: unhealthy Condition: prostate cancer Age Group: adult Sex: M Population Size: 401 Sources: |
Constipation | 22% | 50 mg 1 times / day multiple, oral Recommended Dose: 50 mg, 1 times / day Route: oral Route: multiple Dose: 50 mg, 1 times / day Co-administed with:: LHRH analog Sources: |
unhealthy, adult n = 401 Health Status: unhealthy Condition: prostate cancer Age Group: adult Sex: M Population Size: 401 Sources: |
Back pain | 25% | 50 mg 1 times / day multiple, oral Recommended Dose: 50 mg, 1 times / day Route: oral Route: multiple Dose: 50 mg, 1 times / day Co-administed with:: LHRH analog Sources: |
unhealthy, adult n = 401 Health Status: unhealthy Condition: prostate cancer Age Group: adult Sex: M Population Size: 401 Sources: |
General body pain | 35% | 50 mg 1 times / day multiple, oral Recommended Dose: 50 mg, 1 times / day Route: oral Route: multiple Dose: 50 mg, 1 times / day Co-administed with:: LHRH analog Sources: |
unhealthy, adult n = 401 Health Status: unhealthy Condition: prostate cancer Age Group: adult Sex: M Population Size: 401 Sources: |
Depression | 4% | 50 mg 1 times / day multiple, oral Recommended Dose: 50 mg, 1 times / day Route: oral Route: multiple Dose: 50 mg, 1 times / day Co-administed with:: LHRH analog Sources: |
unhealthy, adult n = 401 Health Status: unhealthy Condition: prostate cancer Age Group: adult Sex: M Population Size: 401 Sources: |
Fracture pathological | 4% | 50 mg 1 times / day multiple, oral Recommended Dose: 50 mg, 1 times / day Route: oral Route: multiple Dose: 50 mg, 1 times / day Co-administed with:: LHRH analog Sources: |
unhealthy, adult n = 401 Health Status: unhealthy Condition: prostate cancer Age Group: adult Sex: M Population Size: 401 Sources: |
Pneumonia | 4% | 50 mg 1 times / day multiple, oral Recommended Dose: 50 mg, 1 times / day Route: oral Route: multiple Dose: 50 mg, 1 times / day Co-administed with:: LHRH analog Sources: |
unhealthy, adult n = 401 Health Status: unhealthy Condition: prostate cancer Age Group: adult Sex: M Population Size: 401 Sources: |
Rhinitis | 4% | 50 mg 1 times / day multiple, oral Recommended Dose: 50 mg, 1 times / day Route: oral Route: multiple Dose: 50 mg, 1 times / day Co-administed with:: LHRH analog Sources: |
unhealthy, adult n = 401 Health Status: unhealthy Condition: prostate cancer Age Group: adult Sex: M Population Size: 401 Sources: |
Urinary incontinence | 4% | 50 mg 1 times / day multiple, oral Recommended Dose: 50 mg, 1 times / day Route: oral Route: multiple Dose: 50 mg, 1 times / day Co-administed with:: LHRH analog Sources: |
unhealthy, adult n = 401 Health Status: unhealthy Condition: prostate cancer Age Group: adult Sex: M Population Size: 401 Sources: |
Alkaline phosphatase increased | 5% | 50 mg 1 times / day multiple, oral Recommended Dose: 50 mg, 1 times / day Route: oral Route: multiple Dose: 50 mg, 1 times / day Co-administed with:: LHRH analog Sources: |
unhealthy, adult n = 401 Health Status: unhealthy Condition: prostate cancer Age Group: adult Sex: M Population Size: 401 Sources: |
Anxiety | 5% | 50 mg 1 times / day multiple, oral Recommended Dose: 50 mg, 1 times / day Route: oral Route: multiple Dose: 50 mg, 1 times / day Co-administed with:: LHRH analog Sources: |
unhealthy, adult n = 401 Health Status: unhealthy Condition: prostate cancer Age Group: adult Sex: M Population Size: 401 Sources: |
Arthritis | 5% | 50 mg 1 times / day multiple, oral Recommended Dose: 50 mg, 1 times / day Route: oral Route: multiple Dose: 50 mg, 1 times / day Co-administed with:: LHRH analog Sources: |
unhealthy, adult n = 401 Health Status: unhealthy Condition: prostate cancer Age Group: adult Sex: M Population Size: 401 Sources: |
Urinary retention | 5% | 50 mg 1 times / day multiple, oral Recommended Dose: 50 mg, 1 times / day Route: oral Route: multiple Dose: 50 mg, 1 times / day Co-administed with:: LHRH analog Sources: |
unhealthy, adult n = 401 Health Status: unhealthy Condition: prostate cancer Age Group: adult Sex: M Population Size: 401 Sources: |
Urination impaired | 5% | 50 mg 1 times / day multiple, oral Recommended Dose: 50 mg, 1 times / day Route: oral Route: multiple Dose: 50 mg, 1 times / day Co-administed with:: LHRH analog Sources: |
unhealthy, adult n = 401 Health Status: unhealthy Condition: prostate cancer Age Group: adult Sex: M Population Size: 401 Sources: |
Weight gain | 5% | 50 mg 1 times / day multiple, oral Recommended Dose: 50 mg, 1 times / day Route: oral Route: multiple Dose: 50 mg, 1 times / day Co-administed with:: LHRH analog Sources: |
unhealthy, adult n = 401 Health Status: unhealthy Condition: prostate cancer Age Group: adult Sex: M Population Size: 401 Sources: |
Hot flashes | 53% | 50 mg 1 times / day multiple, oral Recommended Dose: 50 mg, 1 times / day Route: oral Route: multiple Dose: 50 mg, 1 times / day Co-administed with:: LHRH analog Sources: |
unhealthy, adult n = 401 Health Status: unhealthy Condition: prostate cancer Age Group: adult Sex: M Population Size: 401 Sources: |
Anorexia | 6% | 50 mg 1 times / day multiple, oral Recommended Dose: 50 mg, 1 times / day Route: oral Route: multiple Dose: 50 mg, 1 times / day Co-administed with:: LHRH analog Sources: |
unhealthy, adult n = 401 Health Status: unhealthy Condition: prostate cancer Age Group: adult Sex: M Population Size: 401 Sources: |
Breast pain | 6% | 50 mg 1 times / day multiple, oral Recommended Dose: 50 mg, 1 times / day Route: oral Route: multiple Dose: 50 mg, 1 times / day Co-administed with:: LHRH analog Sources: |
unhealthy, adult n = 401 Health Status: unhealthy Condition: prostate cancer Age Group: adult Sex: M Population Size: 401 Sources: |
Bronchitis | 6% | 50 mg 1 times / day multiple, oral Recommended Dose: 50 mg, 1 times / day Route: oral Route: multiple Dose: 50 mg, 1 times / day Co-administed with:: LHRH analog Sources: |
unhealthy, adult n = 401 Health Status: unhealthy Condition: prostate cancer Age Group: adult Sex: M Population Size: 401 Sources: |
Flatulence | 6% | 50 mg 1 times / day multiple, oral Recommended Dose: 50 mg, 1 times / day Route: oral Route: multiple Dose: 50 mg, 1 times / day Co-administed with:: LHRH analog Sources: |
unhealthy, adult n = 401 Health Status: unhealthy Condition: prostate cancer Age Group: adult Sex: M Population Size: 401 Sources: |
Hyperglycemia | 6% | 50 mg 1 times / day multiple, oral Recommended Dose: 50 mg, 1 times / day Route: oral Route: multiple Dose: 50 mg, 1 times / day Co-administed with:: LHRH analog Sources: |
unhealthy, adult n = 401 Health Status: unhealthy Condition: prostate cancer Age Group: adult Sex: M Population Size: 401 Sources: |
Sweating | 6% | 50 mg 1 times / day multiple, oral Recommended Dose: 50 mg, 1 times / day Route: oral Route: multiple Dose: 50 mg, 1 times / day Co-administed with:: LHRH analog Sources: |
unhealthy, adult n = 401 Health Status: unhealthy Condition: prostate cancer Age Group: adult Sex: M Population Size: 401 Sources: |
Urinary frequency | 6% | 50 mg 1 times / day multiple, oral Recommended Dose: 50 mg, 1 times / day Route: oral Route: multiple Dose: 50 mg, 1 times / day Co-administed with:: LHRH analog Sources: |
unhealthy, adult n = 401 Health Status: unhealthy Condition: prostate cancer Age Group: adult Sex: M Population Size: 401 Sources: |
Vomiting | 6% | 50 mg 1 times / day multiple, oral Recommended Dose: 50 mg, 1 times / day Route: oral Route: multiple Dose: 50 mg, 1 times / day Co-administed with:: LHRH analog Sources: |
unhealthy, adult n = 401 Health Status: unhealthy Condition: prostate cancer Age Group: adult Sex: M Population Size: 401 Sources: |
Dyspepsia | 7% | 50 mg 1 times / day multiple, oral Recommended Dose: 50 mg, 1 times / day Route: oral Route: multiple Dose: 50 mg, 1 times / day Co-administed with:: LHRH analog Sources: |
unhealthy, adult n = 401 Health Status: unhealthy Condition: prostate cancer Age Group: adult Sex: M Population Size: 401 Sources: |
Flu syndrome | 7% | 50 mg 1 times / day multiple, oral Recommended Dose: 50 mg, 1 times / day Route: oral Route: multiple Dose: 50 mg, 1 times / day Co-administed with:: LHRH analog Sources: |
unhealthy, adult n = 401 Health Status: unhealthy Condition: prostate cancer Age Group: adult Sex: M Population Size: 401 Sources: |
Headache | 7% | 50 mg 1 times / day multiple, oral Recommended Dose: 50 mg, 1 times / day Route: oral Route: multiple Dose: 50 mg, 1 times / day Co-administed with:: LHRH analog Sources: |
unhealthy, adult n = 401 Health Status: unhealthy Condition: prostate cancer Age Group: adult Sex: M Population Size: 401 Sources: |
Impotence | 7% | 50 mg 1 times / day multiple, oral Recommended Dose: 50 mg, 1 times / day Route: oral Route: multiple Dose: 50 mg, 1 times / day Co-administed with:: LHRH analog Sources: |
unhealthy, adult n = 401 Health Status: unhealthy Condition: prostate cancer Age Group: adult Sex: M Population Size: 401 Sources: |
Insomnia | 7% | 50 mg 1 times / day multiple, oral Recommended Dose: 50 mg, 1 times / day Route: oral Route: multiple Dose: 50 mg, 1 times / day Co-administed with:: LHRH analog Sources: |
unhealthy, adult n = 401 Health Status: unhealthy Condition: prostate cancer Age Group: adult Sex: M Population Size: 401 Sources: |
Liver function test increased | 7% | 50 mg 1 times / day multiple, oral Recommended Dose: 50 mg, 1 times / day Route: oral Route: multiple Dose: 50 mg, 1 times / day Co-administed with:: LHRH analog Sources: |
unhealthy, adult n = 401 Health Status: unhealthy Condition: prostate cancer Age Group: adult Sex: M Population Size: 401 Sources: |
Myasthenia | 7% | 50 mg 1 times / day multiple, oral Recommended Dose: 50 mg, 1 times / day Route: oral Route: multiple Dose: 50 mg, 1 times / day Co-administed with:: LHRH analog Sources: |
unhealthy, adult n = 401 Health Status: unhealthy Condition: prostate cancer Age Group: adult Sex: M Population Size: 401 Sources: |
Weight loss | 7% | 50 mg 1 times / day multiple, oral Recommended Dose: 50 mg, 1 times / day Route: oral Route: multiple Dose: 50 mg, 1 times / day Co-administed with:: LHRH analog Sources: |
unhealthy, adult n = 401 Health Status: unhealthy Condition: prostate cancer Age Group: adult Sex: M Population Size: 401 Sources: |
Chest pain | 8% | 50 mg 1 times / day multiple, oral Recommended Dose: 50 mg, 1 times / day Route: oral Route: multiple Dose: 50 mg, 1 times / day Co-administed with:: LHRH analog Sources: |
unhealthy, adult n = 401 Health Status: unhealthy Condition: prostate cancer Age Group: adult Sex: M Population Size: 401 Sources: |
Cough increased | 8% | 50 mg 1 times / day multiple, oral Recommended Dose: 50 mg, 1 times / day Route: oral Route: multiple Dose: 50 mg, 1 times / day Co-administed with:: LHRH analog Sources: |
unhealthy, adult n = 401 Health Status: unhealthy Condition: prostate cancer Age Group: adult Sex: M Population Size: 401 Sources: |
Hypertension | 8% | 50 mg 1 times / day multiple, oral Recommended Dose: 50 mg, 1 times / day Route: oral Route: multiple Dose: 50 mg, 1 times / day Co-administed with:: LHRH analog Sources: |
unhealthy, adult n = 401 Health Status: unhealthy Condition: prostate cancer Age Group: adult Sex: M Population Size: 401 Sources: |
Paresthesia | 8% | 50 mg 1 times / day multiple, oral Recommended Dose: 50 mg, 1 times / day Route: oral Route: multiple Dose: 50 mg, 1 times / day Co-administed with:: LHRH analog Sources: |
unhealthy, adult n = 401 Health Status: unhealthy Condition: prostate cancer Age Group: adult Sex: M Population Size: 401 Sources: |
Pharyngitis | 8% | 50 mg 1 times / day multiple, oral Recommended Dose: 50 mg, 1 times / day Route: oral Route: multiple Dose: 50 mg, 1 times / day Co-administed with:: LHRH analog Sources: |
unhealthy, adult n = 401 Health Status: unhealthy Condition: prostate cancer Age Group: adult Sex: M Population Size: 401 Sources: |
Bone pain | 9% | 50 mg 1 times / day multiple, oral Recommended Dose: 50 mg, 1 times / day Route: oral Route: multiple Dose: 50 mg, 1 times / day Co-administed with:: LHRH analog Sources: |
unhealthy, adult n = 401 Health Status: unhealthy Condition: prostate cancer Age Group: adult Sex: M Population Size: 401 Sources: |
Gynecomastia | 9% | 50 mg 1 times / day multiple, oral Recommended Dose: 50 mg, 1 times / day Route: oral Route: multiple Dose: 50 mg, 1 times / day Co-administed with:: LHRH analog Sources: |
unhealthy, adult n = 401 Health Status: unhealthy Condition: prostate cancer Age Group: adult Sex: M Population Size: 401 Sources: |
Rash | 9% | 50 mg 1 times / day multiple, oral Recommended Dose: 50 mg, 1 times / day Route: oral Route: multiple Dose: 50 mg, 1 times / day Co-administed with:: LHRH analog Sources: |
unhealthy, adult n = 401 Health Status: unhealthy Condition: prostate cancer Age Group: adult Sex: M Population Size: 401 Sources: |
Urinary tract infection | 9% | 50 mg 1 times / day multiple, oral Recommended Dose: 50 mg, 1 times / day Route: oral Route: multiple Dose: 50 mg, 1 times / day Co-administed with:: LHRH analog Sources: |
unhealthy, adult n = 401 Health Status: unhealthy Condition: prostate cancer Age Group: adult Sex: M Population Size: 401 Sources: |
Overview
CYP3A4 | CYP2C9 | CYP2D6 | hERG |
---|---|---|---|
OverviewOther
Other Inhibitor | Other Substrate | Other Inducer |
---|---|---|
Drug as perpetrator
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
major [IC50 7 uM] | ||||
minor [IC50 123 uM] | ||||
minor [IC50 44 uM] | ||||
minor [IC50 49 uM] | ||||
minor [IC50 58 uM] | ||||
yes [Inhibition 40 uM] | ||||
yes [Ki 11.9 uM] | ||||
Sources: https://pubmed.ncbi.nlm.nih.gov/15509184/ Page: 2.0 |
yes |
Drug as victim
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
Sources: https://pubmed.ncbi.nlm.nih.gov/15509184/ Page: 2.0 |
likely | unlikely (co-administration study) Comment: this isoenzyme is also responsible for the metabolism of (R)-bicalutamide; (S)-Bicalutamide is metabolised in vitro by CYP3A4 Sources: https://pubmed.ncbi.nlm.nih.gov/15509184/ Page: 2.0 |
||
low | ||||
low | ||||
major | ||||
minor | ||||
minor | ||||
no | ||||
no | ||||
no | ||||
no | ||||
no | ||||
no | ||||
no | ||||
no | ||||
no | ||||
no |
PubMed
Title | Date | PubMed |
---|---|---|
Partial agonist/antagonist properties of androstenedione and 4-androsten-3beta,17beta-diol. | 2004 Aug |
|
The androgen receptor co-activator CBP is up-regulated following androgen withdrawal and is highly expressed in advanced prostate cancer. | 2004 Oct |
|
Changes in androgen receptor nongenotropic signaling correlate with transition of LNCaP cells to androgen independence. | 2004 Oct 1 |
|
Evaluation of tamoxifen and anastrozole in the prevention of gynecomastia and breast pain induced by bicalutamide monotherapy of prostate cancer. | 2005 Feb 1 |
|
Microarray analysis of bicalutamide action on telomerase activity, p53 pathway and viability of prostate carcinoma cell lines. | 2005 Jan |
|
The ErbB3-binding protein Ebp1 suppresses androgen receptor-mediated gene transcription and tumorigenesis of prostate cancer cells. | 2005 Jul 12 |
|
Direct agonist/antagonist functions of dehydroepiandrosterone. | 2005 Nov |
|
Antiandrogen bicalutamide promotes tumor growth in a novel androgen-dependent prostate cancer xenograft model derived from a bicalutamide-treated patient. | 2005 Nov 1 |
|
Possible role of adaptive mutation in resistance to antiandrogen in prostate cancer cells. | 2005 Nov 1 |
|
Influence of bicalutamide with or without tamoxifen or anastrozole on insulin-like growth factor 1 and binding proteins in prostate cancer patients. | 2006 Apr-Jun |
|
Distinct regulation by steroids of messenger RNAs for FSHR and CYP19A1 in bovine granulosa cells. | 2006 Aug |
|
Persistence of prostatic intraepithelial neoplasia after effective chemoprevention of microscopic prostate cancer with antiandrogen in a rat model. | 2006 Jan |
|
Prostate specific antigen expression does not necessarily correlate with prostate cancer cell growth. | 2006 Jul |
|
Conditional expression of PTEN alters the androgen responsiveness of prostate cancer cells. | 2006 Jul 1 |
|
Androgen induction of prostate cancer cell invasion is mediated by ezrin. | 2006 Oct 6 |
|
Therapeutic potential of CDK inhibitor NU2058 in androgen-independent prostate cancer. | 2007 Dec 6 |
|
Labeling and identification of LNCaP cell surface proteins: a pilot study. | 2007 Jun 15 |
|
Reactive oxygen species mediate androgen receptor- and serum starvation-elicited downstream signaling of ADAM9 expression in human prostate cancer cells. | 2007 May 15 |
|
Gefitinib and bicalutamide show synergistic effects in primary cultures of prostate cancer derived from androgen-dependent naive patients. | 2007 Nov |
|
Oriental herbs as a source of novel anti-androgen and prostate cancer chemopreventive agents. | 2007 Sep |
|
PC-1/PrLZ contributes to malignant progression in prostate cancer. | 2007 Sep 15 |
|
Effects of dihydrotestosterone on differentiation and proliferation of human mesenchymal stem cells and preadipocytes. | 2008 Dec 16 |
|
Downregulation of thymosin beta4 expression by androgen in prostate cancer LNCaP cells. | 2008 Mar-Apr |
|
Chronic azacitidine treatment results in differentiating effects, sensitizes against bicalutamide in androgen-independent prostate cancer cells. | 2008 May 15 |
|
Spectrophotometric estimation of bicalutamide in tablets. | 2008 Nov |
|
A novel dietary flavonoid fisetin inhibits androgen receptor signaling and tumor growth in athymic nude mice. | 2008 Oct 15 |
|
Genome-wide impact of androgen receptor trapped clone-27 loss on androgen-regulated transcription in prostate cancer cells. | 2009 Apr 1 |
|
Interactions of methoxyacetic acid with androgen receptor. | 2009 Jul 15 |
|
Interleukin-6 increases prostate cancer cells resistance to bicalutamide via TIF2. | 2009 Mar |
|
Inhibition of androgen receptor transcriptional activity as a novel mechanism of action of arsenic. | 2009 Mar |
|
Interleukin-6 stimulation of growth of prostate cancer in vitro and in vivo through activation of the androgen receptor. | 2009 Mar |
|
Development of a second-generation antiandrogen for treatment of advanced prostate cancer. | 2009 May 8 |
|
Is prophylactic breast radiotherapy necessary in all patients with prostate cancer and gynecomastia and/or breast pain? | 2010 Aug |
|
Androgen-regulated expression of arginase 1, arginase 2 and interleukin-8 in human prostate cancer. | 2010 Aug 11 |
|
REDD1 is a major target of testosterone action in preventing dexamethasone-induced muscle loss. | 2010 Mar |
|
Resveratrol regulates the PTEN/AKT pathway through androgen receptor-dependent and -independent mechanisms in prostate cancer cell lines. | 2010 Nov 15 |
|
Androgen receptor-mTOR crosstalk is regulated by testosterone availability: implication for prostate cancer cell survival. | 2010 Oct |
|
Testosterone, not 5α-dihydrotestosterone, stimulates LRH-1 leading to FSH-independent expression of Cyp19 and P450scc in granulosa cells. | 2011 Apr |
|
Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. | 2011 Jul |
|
Unexpected binding orientation of bulky-B-ring anti-androgens and implications for future drug targets. | 2011 Jun 9 |
|
Discovery of aryloxy tetramethylcyclobutanes as novel androgen receptor antagonists. | 2011 Nov 10 |
|
Biological properties of androgen receptor pure antagonist for treatment of castration-resistant prostate cancer: optimization from lead compound to CH5137291. | 2011 Sep |
|
Inhibitors of androgen receptor activation function-2 (AF2) site identified through virtual screening. | 2011 Sep 22 |
|
Red ginseng and 20(S)-Rg3 control testosterone-induced prostate hyperplasia by deregulating androgen receptor signaling. | 2012 Jul |
|
Androgen signaling promotes translation of TMEFF2 in prostate cancer cells via phosphorylation of the α subunit of the translation initiation factor 2. | 2013 |
|
Endocrine disruptors fludioxonil and fenhexamid stimulate miR-21 expression in breast cancer cells. | 2013 Jan |
|
Dehydroepiandrosterone post-transcriptionally modifies CYP1A2 induction involving androgen receptor. | 2013 May 25 |
|
Bisphenol A affects androgen receptor function via multiple mechanisms. | 2013 May 25 |
|
Targeting cell cycle and hormone receptor pathways in cancer. | 2013 Nov 28 |
|
Therapeutic targeting of BET bromodomain proteins in castration-resistant prostate cancer. | 2014 Jun 12 |
Sample Use Guides
one 50 mg tablet once daily (morning or evening), with or without food
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/19285710
Primary tumor cultures and PCa cell lines were treated with bicalutamide (0.1-10 uM) in the presence of dehydrotestosterone (10(-12) M) for 4 days. After bicalutamide treatment, no significant differences in the concentration that inhibits 50% were found among the different tumor cell lines (P = .081).
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Brand Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
WHO-VATC |
QL02BB03
Created by
admin on Fri Jun 25 21:02:59 UTC 2021 , Edited by admin on Fri Jun 25 21:02:59 UTC 2021
|
||
|
NDF-RT |
N0000000243
Created by
admin on Fri Jun 25 21:02:59 UTC 2021 , Edited by admin on Fri Jun 25 21:02:59 UTC 2021
|
||
|
WHO-ATC |
L02AE51
Created by
admin on Fri Jun 25 21:02:59 UTC 2021 , Edited by admin on Fri Jun 25 21:02:59 UTC 2021
|
||
|
NCI_THESAURUS |
C146993
Created by
admin on Fri Jun 25 21:02:59 UTC 2021 , Edited by admin on Fri Jun 25 21:02:59 UTC 2021
|
||
|
WHO-ATC |
L02BB03
Created by
admin on Fri Jun 25 21:02:59 UTC 2021 , Edited by admin on Fri Jun 25 21:02:59 UTC 2021
|
||
|
NDF-RT |
N0000175560
Created by
admin on Fri Jun 25 21:02:59 UTC 2021 , Edited by admin on Fri Jun 25 21:02:59 UTC 2021
|
||
|
LIVERTOX |
105
Created by
admin on Fri Jun 25 21:02:59 UTC 2021 , Edited by admin on Fri Jun 25 21:02:59 UTC 2021
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
A0Z3NAU9DP
Created by
admin on Fri Jun 25 21:02:59 UTC 2021 , Edited by admin on Fri Jun 25 21:02:59 UTC 2021
|
PRIMARY | |||
|
1071202
Created by
admin on Fri Jun 25 21:02:59 UTC 2021 , Edited by admin on Fri Jun 25 21:02:59 UTC 2021
|
PRIMARY | USP-RS | ||
|
BICALUTAMIDE
Created by
admin on Fri Jun 25 21:02:59 UTC 2021 , Edited by admin on Fri Jun 25 21:02:59 UTC 2021
|
PRIMARY | |||
|
367
Created by
admin on Fri Jun 25 21:02:59 UTC 2021 , Edited by admin on Fri Jun 25 21:02:59 UTC 2021
|
PRIMARY | |||
|
SUB05817MIG
Created by
admin on Fri Jun 25 21:02:59 UTC 2021 , Edited by admin on Fri Jun 25 21:02:59 UTC 2021
|
PRIMARY | |||
|
2375
Created by
admin on Fri Jun 25 21:02:59 UTC 2021 , Edited by admin on Fri Jun 25 21:02:59 UTC 2021
|
PRIMARY | |||
|
90357-06-5
Created by
admin on Fri Jun 25 21:02:59 UTC 2021 , Edited by admin on Fri Jun 25 21:02:59 UTC 2021
|
PRIMARY | |||
|
2863
Created by
admin on Fri Jun 25 21:02:59 UTC 2021 , Edited by admin on Fri Jun 25 21:02:59 UTC 2021
|
PRIMARY | |||
|
C053541
Created by
admin on Fri Jun 25 21:02:59 UTC 2021 , Edited by admin on Fri Jun 25 21:02:59 UTC 2021
|
PRIMARY | |||
|
7021
Created by
admin on Fri Jun 25 21:02:59 UTC 2021 , Edited by admin on Fri Jun 25 21:02:59 UTC 2021
|
PRIMARY | |||
|
C1599
Created by
admin on Fri Jun 25 21:02:59 UTC 2021 , Edited by admin on Fri Jun 25 21:02:59 UTC 2021
|
PRIMARY | |||
|
83008
Created by
admin on Fri Jun 25 21:02:59 UTC 2021 , Edited by admin on Fri Jun 25 21:02:59 UTC 2021
|
PRIMARY | RxNorm | ||
|
90357-06-5
Created by
admin on Fri Jun 25 21:02:59 UTC 2021 , Edited by admin on Fri Jun 25 21:02:59 UTC 2021
|
PRIMARY | |||
|
CHEMBL409
Created by
admin on Fri Jun 25 21:02:59 UTC 2021 , Edited by admin on Fri Jun 25 21:02:59 UTC 2021
|
PRIMARY | |||
|
7655
Created by
admin on Fri Jun 25 21:02:59 UTC 2021 , Edited by admin on Fri Jun 25 21:02:59 UTC 2021
|
PRIMARY | |||
|
M2474
Created by
admin on Fri Jun 25 21:02:59 UTC 2021 , Edited by admin on Fri Jun 25 21:02:59 UTC 2021
|
PRIMARY | Merck Index | ||
|
DB01128
Created by
admin on Fri Jun 25 21:02:59 UTC 2021 , Edited by admin on Fri Jun 25 21:02:59 UTC 2021
|
PRIMARY |
ACTIVE MOIETY